Pharmaceuticals

FDA Grants Fast Track Designation to 9MW3011

SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Fast Track Designation (FTD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (P...

2023-09-22 08:00 2456

Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function

SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced its partnership with Aditum Bio to create Celexor Bio (Celexor), a ne...

2023-09-21 21:00 5491

Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL

SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Products Administration (NMPA) has granted priority review status to golidocitinib, Dizal's investigational JAK1-only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma (r...

2023-09-21 20:26 2489

AVANCE CLINICAL APPOINTS US-BASED EXECUTIVES - SVP SCIENTIFIC AND REGULATORY AFFAIRS, AND DIRECTOR BUSINESS DEVELOPMENT

ADELAIDE, Australia and RALEIGH, N.C., Sept. 21, 2023 /PRNewswire/ -- Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, announces two key appointments in the US to support its continued global growth.

2023-09-21 19:30 2618

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL).   - ATG-031,discovered and developed in-house by Antengene,is the world's firs...

2023-09-21 18:05 3088

Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology

SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of the treatment of metastatic pancreat...

2023-09-21 16:00 2350

Yuyu Healthcare Conducts Global Promotion at Vitafoods Asia 2023

SEOUL, South Korea, Sept. 21, 2023 /PRNewswire/ -- Yuyu Healthcare will participate in the Vitafoods Asia 2023 event inBangkok, Thailand with the goal of entering the global market. Yu...

2023-09-21 14:06 7069

Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB

HANGZHOU, China, Sept. 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, today announced the successful completion of Series C2 financing. This round of financing was jointly participated by the Shaox...

2023-09-21 08:00 5008

Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets

SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today it has entered into a collaboration and license...

2023-09-21 07:05 3948

European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

* Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients inEurope die annually from the disease² * ORSERDU is the first treatment specifically for patients with ER+, HE...

2023-09-20 23:27 3543

Hepagene Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for HPG7233 THR Beta Agonist

HONG KONG and NANJING, China, Sept. 20, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its HPG7233, an agonist of Thyroid H...

2023-09-20 22:00 2059

Taiwan's Premier Health Brand Unveils Best Quality Pineapple Enzyme for Digestive Health

NISORO HEALTH introduces high-quality Pineapple Enzyme, a digestive elixir blendingTaiwan's pineapples and LJ88 probiotics. It enhances digestion, promotes gut health, and is suitable for all ages. TAIPEI, Sept. 20, 2023 /PRNewswire/ -- Taiwan is renowned for its exceptional products, and NISORO...

2023-09-20 21:00 2567

Double Honors: Sanyou Bio Earns "Most Trusted Biopharmaceutical CXO Partner" and "Most Influential Partner of the Year" Awards

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Sanyou Bio's consecutive wins reflect our clients' trust, and our proven track record, raising expectations for our future. This recognition from peers and industry experts motivate us to remain committed to our mission, and to consistently provide high-qu...

2023-09-20 20:00 1862

WuXi XDC Launches New Commercial Manufacturing Facilities

* New commercial facilities offer one-stop manufacturing services for antibody intermediates, bioconjugate drug substance and drug product * Doubled capacity provides greater support to the rapidly growing global bioconjugate industry   WUXI, China, Sept. 20, 2023 /PRNewswire/ -- WuXi XDC, a ...

2023-09-20 18:51 2720

The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has announced that the multinatio...

2023-09-20 15:52 2622

AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmologic, neurological and psychiat...

2023-09-20 09:00 4443

Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines inGreater China and other parts of Asia, announced today that the Center for Drug E...

2023-09-20 08:26 3200

Cerecin strengthens position in neurometabolism with addition to pipeline

* Cerecin completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and usein positron emission tomography (PET) studies of ketone body metabolism * Company expands ketogenic platform following pilot data of CER-0001 in migraine and infantile spasms. ...

2023-09-19 19:39 3367

Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment

TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway), a biopharmaceutical company focusing on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, announced the completion of subject recruitment in the CBL-0201EFP Phase 2-stage...

2023-09-19 11:16 2129

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities. The current expansion is in response to the growing demand...

2023-09-19 09:16 3726
1 ... 217218219220221222223 ... 351